Literature DB >> 4114458

Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.

U K Rinne, V Sonninen, T Sirtola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4114458     DOI： 10.1007/bf00316422

Source DB:  PubMed          Journal:  Z Neurol        ISSN： 0012-1037


× No keyword cloud information.
  51 in total

1.  Treatment of parkinsonism with L-dopa (study of 105 patients).

Authors:  H L Klawans; J S Garvin
Journal:  Dis Nerv Syst       Date:  1969-11

2.  Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain.

Authors:  J Constantinidis; G Bartholini; R Tissot; A Pletscher
Journal:  Experientia       Date:  1968-02-15

3.  [The capillary enzyme barrier for DOPA at the level of some brain stem nuclei in the rat].

Authors:  J Constantinidis; G Bartholini; F Geissbühler; R Tissot
Journal:  Experientia       Date:  1970-04-15

4.  L-dihydroxyphenylalanine: effect on S-adenosylmethionine in brain.

Authors:  R J Wurtman; S Matthysse; J Stephenson; R Baldessarini
Journal:  Science       Date:  1970-07-24       Impact factor: 47.728

5.  [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].

Authors:  W Kaufmann; P Butz; M Wiesendanger
Journal:  Dtsch Z Nervenheilkd       Date:  1970

6.  Further studies on tryptophan hydroxylase in rat brainstem and beef pineal.

Authors:  E Jequier; D S Robinson; W Lovenberg; A Sjoerdsma
Journal:  Biochem Pharmacol       Date:  1969-05       Impact factor: 5.858

7.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

8.  The metabolism of orally administered L-Dopa in Parkinsonism.

Authors:  D B Calne; F Karoum; C R Ruthven; M Sandler
Journal:  Br J Pharmacol       Date:  1969-09       Impact factor: 8.739

Review 9.  Dopamine (3-hydroxytyramine) and brain function.

Authors:  O Hornykiewicz
Journal:  Pharmacol Rev       Date:  1966-06       Impact factor: 25.468

10.  L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.

Authors:  M D Yahr; R C Duvoisin; M M Hoehn; M J Schear; R E Barrett
Journal:  Trans Am Neurol Assoc       Date:  1968
View more
  9 in total

1.  Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.

Authors:  G Campanella; S Algeri; C Cerletti; E Dolfini; A Jori; F Rinaldi
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

2.  L-dopa level in plasma, primary condition for the kinetic effect.

Authors:  W Birkmayer; W Danielcyk; E Neumayer; P Riederer
Journal:  J Neural Transm       Date:  1973       Impact factor: 3.575

3.  [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].

Authors:  E Schneider; P A Fischer; P Jacobi; H Maxion
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1973-03-19

Review 4.  Diagnosis and treatment of Parkinson disease: molecules to medicine.

Authors:  Joseph M Savitt; Valina L Dawson; Ted M Dawson
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

Review 5.  Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

6.  Mortality of patients with Parkinson's disease treated with levodopa.

Authors:  R J Marttila; U K Rinne; T Siirtola; V Sonninen
Journal:  J Neurol       Date:  1977-10-07       Impact factor: 4.849

7.  L-deprenyl treatment of on-off phenomena in Parkinson's disease.

Authors:  U K Rinne; T Siirtola; V Sonninen
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

8.  Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.

Authors:  Teodoro Bottiglieri; Erland Arning; Brandi Wasek; Viyada Nunbhakdi-Craig; Jean-Marie Sontag; Estelle Sontag
Journal:  J Neurosci       Date:  2012-07-04       Impact factor: 6.167

9.  Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.

Authors:  U K Rinne; E Birket-Smith; E Dupont; E Hansen; M Hyyppä; R Marttila; B Mikkelsen; H Pakkenberg; J Presthus
Journal:  J Neurol       Date:  1975-12-02       Impact factor: 4.849
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.